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Abstract: 
The inflammatory cytokine, Macrophage Migration Inhibitory Factor, was initially 
isolated in the 1970s as a chemokine involved with inhibition of random movement in 
Macrophages but has also been linked with many other components of the immune system and 
even foetal development. It is released almost-ubiquitously, during inflammation, with both pro-
inflammatory and anti-inflammatory activities. One key regulator of inflammation is the 
Unfolded Protein Response. during which the Endoplasmic Reticulum within cells regulates 
protein flux within the ER lumen, especially when that load is beyond the capacity of the ER to 
successfully process. As part of the UPR response there is a stop in global translation, enhanced 
transcription and translation of chaperone proteins, increased ER size and capacity and 
eventually activation of the apoptosis pathways if the protein load does not reduce to a level 
within the ER’s capacity. The UPR is controlled via the transduction proteins, IRE1, PERK and 
ATF6. Because of the UPR’s effect on cellular health and known links to inflammation it was 
decided to investigate the effects of MIF on UPR activation within cells. Using two different 
reporter constructs (ATF4.EYFP-N1 or XBP-1.EeYFP-N1) which monitor activation IRE1 and PERK 
the effects of MIF on UPR activation in HeLa and SH-SY5Y cells was assessed. The observed 
results show that MIF exerts a  marginal suppressive effect on both the IRE1 and PERK between 
with some variation in the effects of MIF on epithelial (HeLa) or neuronal (SH-SY5Y) origins. This 
data suggests that MIF may reduce the activation of apoptotic responses within these cells via 
activation UPR and the PERK pathway through suppression of JNK activity via the noncanonical 
MIF receptor JAB1. Modulation of UPR responses by MIF would have important downstream 
effects on the development of auto-inflammatory conditions and neuropathies include 
Alzheimer’s disease due to the suppressed UPRs inability to resolve the pathological protein 
load.   
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1 Introduction:  
1.1 Inflammation: 
Complex multicellular organisms, by their nature, have a series of mechanisms to 
protect against exogenous and endogenous threats to the organism and without these 
protective measures they would have a brief existence. One of these defences is immune 
mediated inflammation.  
Inflammation is the reaction of a cell, tissue, or organism to a potential source of 
damage by the release of cytokines (a diverse series of poly-peptide based signallers) that cause 
a wide variety of different effects. These include: capillary ‘leakiness’ and the laying down of 
new blood vessels; the recruitment of tissue resident macrophages, dendritic cells and the 
adaptive immune system; the repair or renewal of tissue and finally the resolution of the 
inflammation; that all work through a common set of mediators e.g., nuclear factor kappa-light-
chain-enhancer of activated B cells (NF-κB). However, there are at least two ‘depths’ of 
inflammation; Acute and Chronic. These ‘depths’ are not simply phases that inflammation 
passes through on its way to resolution. (Sugimoto et al., 2016) chronic inflammation will 
typically follow an acute stage but are discrete events that can occur in any order. Indeed, acute 
inflammatory responses are more frequently the consequence of infection and wounds that 
resolve without a chronic phase. In contrast, conditions such as a tumour or autoimmune 
disease, are more likely present chronic inflammation when the disease is diagnosed.   
 For the case of infections, dendritic cells, tissue resident macrophages and neutrophils 
drive inflammation, reacting to the presence of a Pathogen Associated Molecular Patterns 
(PAMP(s)) via Pathogen Recognition Receptors (PRR). Several PRR families exist, including Toll-
Like Receptors (TLR(s)), C-type Lectin Receptors and NOD-Like Receptors. Looking at one family, 
the TLRs (1-13 in mammals), shows how a constellation of different receptors can lead to the 
same outcome. The TLR family (except 3 and 10) activate NF-κB signalling via the classical 
MyD88/IRAK route leading to IκB phosphorylation by IKK/NEMO and therefore Inflammation 
(Alexopoulou et al., 2001; Jiang et al., 2016) 
 This activation causes the upregulation of many pro-inflammatory cytokines and 
chemokines, leading to the onset of inflammation. This picture is complicated somewhat by the 
fact that NF-κB signalling has been shown to have an anti-inflammatory effect as well as a pro-
inflammatory effect, in certain lineages but also at certain times during an inflammatory event 
(Sugimoto et al., 2016), so that inflammation is, in theory, self-limiting. (Table 1.1). 
 
2 
 
  
 
Inflammation is, of course, not just controlled by PRRs. Nor is NF-κB the only 
inflammatory transcription factor involved; Activator Protein 1 (AP-1) and Interferon Regulatory 
Factors (IFN family) are also important players in these processes; but all of these can be 
activated far from the source of the infection due to another important part of the inflammation 
response: cytokines. These are mostly well categorised but a specific, non-classical cytokine, 
Macrophage Migration Inhibitory Factor is a known, modulator of many inflammation signals 
including NF-κ However despite being one of the first cytokines discovered MIF remains an 
enigmatic signalling player and many of its observed biological effects have not been fully 
characterised. 
  
Table 1.1: A list of prominent immune factors involved in NF-κB regulated inflammation.  
Protein Pro/Anti-
Inflammatory 
Cell lineages  References 
Interferon γ  Pro T and NK-cells (Sica et al., 1997) 
TNFα Pro Ubiquitous  (Collart, Baeuerle and Vassalli, 
1990) 
IL-1a and b Pro Ec, Ma (Hiscott et al., 1993) 
IL-2 Pro T-cells (Hoyos et al., 1989) 
IL-6 Pro Ec, Ma and T-cells (Son et al., 2008) 
IL-8 Pro  Ec, Ma  (Sanacora et al., 2013) 
IL-9 Pro T-cells (Zhu et al., 1996) 
IL-10 Anti Ma, T-cells (Cao et al., 2006; Hou et al., 2012) 
IL-11 Pro Bone Marrow Stroma (Bitko et al., 1997) 
IL-17 Pro Bone Marrow Stroma (Shen et al., 2006) 
CD74/Invariant 
Chain II 
Pro/Anti Ma, Dendritic (Pessara and Koch, 1990) 
MHC 1 Pro Ubiquitous (Johnson and Pober, 1994) 
MIF Pro Ubiquitous (Bloom and Bennett, 1966) 
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1.2 Macrophage Migration Inhibitory Factor: 
1.2.1 History and Structure: 
Macrophage Migration Inhibitory Factor (MIF) was discovered in the 1960s when it was 
identified as proteinaceous factor which inhibited the random migration of macrophages and 
was associated with delayed hyper-sensitivity (Bloom and Bennett, 1966; David, 1966). 
However, the protein itself was not characterised until 20 years later when it was finally cloned 
(Weiser et al., 1989; Bendrat et al., 1997) 
Subsequent research has shown that MIF is a pleiotropic cytokine, with much of its 
effects pro-inflammatory, counteracting the anti-inflammatory action of corticosteroids 
(Bernhagen et al., 1993; Roger et al., 2005; Fan et al., 2013)and leading to the upregulation of 
NF-κB, ETS and AP-1. MIF, at first glance, seems to perform some more esoteric functions within 
organisms, for example the vascularisation of lung tissue in foetus and neonates (Roger et al., 
2017). The most obvious effect of MIF on cells is the halting of the random movement of 
leukocytes through tissues and then acting as a chemoattractant, through CXCR2/CXCR4/CD74 
(Klasen et al., 2014), bringing the immune system to the site of the infection/damage. MIF has 
also been shown to potentiate signals controlling transcriptional regulation of TLR-4 expression. 
(Roger et al., 2005; Kudrin et al., 2006). This occurs through ETS signalling and takes the form of 
a positive feedback loop in which more TLR4 production feeds more MIF production.  
The crystal structure of MIF which was elucidated in 1996 showed that it can form a 
homotrimer (Figure 1.1 ). However, it is unclear whether MIF exists in vivo as a homotrimer or 
as a dimer or monomer as all forms have been identified during in vitro biochemical studies. 
(Sun et al., 1996; Fan et al., 2013; Gordon-Weeks et al., 2015). MIF is encoded by a gene on 
chromosome 22 and does not share homology with any of the other families of cytokines. 
However, it does share homology with a second MIF-like protein called D-dopachrome 
tautomerase (D-DT, sometimes called MIF2) whose gene is also found closely linked to the MIF 
gene on chromosome 22 (Merk et al., 2012). The MIF promoter contains DNA binding domains 
for other transcription factors; including AP-1, GATA Family, NF-κB and CREB allowing for its 
upregulation from a variety of external signals. (Calandra et al., 2003) and unusually has, two 
different enzymatic activities: oxidoreductase and dopachrome tautomerase (Bendrat et al., 
1997; Rosengren et al., 1997). These activities have been shown to have physiological relevance 
as the knockout of the oxidoreductase has been shown to modulate the damping down of 
neuronal signalling (Matsuura et al., 2007) and the tautomerase activity has been shown to 
interact with CD74-CD44 for canonical MIF signalling (Leng et al., 2003).  
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Figure 1.1: The 3d ribbon structure of human Macrophage Migration 
Inhibitory Factor (MIF). This image is adapted from Gordon-Weeks et al., 
2015 is two ribbon diagrams for MIF. Ribbon 1 is MIF’s monomer. In blue is 
the oxidoreductase component and the red is the CXCR2 motif. The yellow 
in the monomer is the tautomerase catalytic site conferred by a proline. 
Ribbon 2 is the trimer, the back bones of which are coloured cyan, purple, 
and green. Components shown in the monomer retain their colour. 
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Another unusual feature of MIF is even though it functions as an extracellular signalling 
molecule it lacks an N- terminal leader sequence, such as the ER signal peptide. It is not, 
therefore, completely understood how MIF is secreted out of a cell. However, MIF is produced 
constitutively and almost ubiquitously in humans (Merk et al., 2009); with MIF being 
‘rediscovered’ in the 90s as a hormone released from the anterior pituitary gland upon sensing 
LPS, which can lead to toxaemia; as well as epithelial cells, T-cells, granulocytes and 
macrophages (Bernhagen et al., 1993; Calandra et al., 1994). MIF transcription is not 
upregulated upon treatment with a PAMP/Cytokine as it is constitutively expressed and stored 
in vesicles which are released by the cell after receipt of these inflammation signals (Bernhagen 
et al., 1994). 
MIF appears to be well conserved in eukaryotes, with unicellular eukaryotes such as 
Plasmodium falciparum or more ‘simple’ multicellular animals, such as T. spiralis having their 
own MIF homologue. These other MIF homologues are evolutionarily very distant from the 
mammalian MIFs (25-46% protein homology, who share a ~95% homology with each other). 
Interestingly, MIFs from these other eukaryotes have some unique peculiarities and while many 
share the tautomerase activity (Tan et al., 2001), a large number lack of the oxidoreductase 
activity, a feature they share with mammalian D-DT/MIF2s (Merk et al., 2012).  
1.2.2 Mechanism of MIF’s Action: 
An open question about MIF is exactly how it performs its functions. Studies have shown 
that MIF does not always behave like a classical cytokine, able to cause effects by itself, but acts 
in a secondary capacity modulating other signals (Kudrin et al., 2006). One of the key challenges 
in characterising the molecular mechanisms of MIF’s activities is that it has been postulated that 
it operates through multiple receptors. These include the extracellular CD74 -CD44 receptor 
complexes and the CXCR family, (Leng et al., 2003; Leng and Bucala, 2006; Shi et al., 2006; 
Schwartz et al., 2009) as well as intracellular receptors like JAB-1 (Kleemann et al., 2000) and 
thioredoxin-interacting protein (TXNIP), (Kim et al., 2017). For its intracellular receptors, cell 
entry is believed to be mediated through non-receptor mediated endocytosis, but it could also 
be due to the interaction with Thioredoxin-1 (TRX) (Son et al., 2009). Despite these receptors 
being identified it has not been elucidated how the MIF-receptor complex imparts effects onto 
downstream pathways (Kleemann et al., 2000). 
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What is known though is that MIF signal transduction processes impinges on the 
Mitogen Activated Protein Kinase (MAPK) pathway (Amin et al., 2003; Lue et al., 2006, 2011). 
The MAPK signalling pathways are a series of nearly identical chains of receptors, transductors 
and effectors (Figure 1.2) involved in a wide variety of processes including reception of PAMP 
and cytokine derived signals. Through the MAPK pathway, MIF is believed to cause many 
different effects that generally centre on modulating the immune response to a more aggressive 
clearance of the cause of the MIF release.   
 One final place the MAPK pathways converge is the Molecular Target of Rapamycin 
Complexes. These, mTORC1 and mTORC2, are relatively recent discoveries (Gonzalez and Rallis, 
2017) but have been shown to have major control on cell survival, reaction to starvation and 
oxidative stress. It has been shown that active MAPK impingement on the mTORC1, via the 
phosphorylation of TSC1/2, has the effect of potentiating any other signal entering the mTORC1 
path (Carracedo et al., 2008). Indeed, some of those more esoteric functions of MIF such as the 
lung vascularisation in neonates could be driven by the interaction of MIF and mTORC1 because 
of mTORC1s downstream effect of causing VEGF up-regulation (Roger et al., 2017).  
 Another extremely important physiological process within the cell is the control of 
protein production and folding, especially important for extracellular proteins, and this is 
controlled by the Endoplasmic Reticulum.  
Figure 1.2: A diagram of the ERK1/2 pathway. ERK1/2 is a well-defined MAPK signalling pathway that can be 
briefly stated as: Receptor activation which leads Ras phosphorylation and activation. Ras recruites Raf (Raf-
1, B-Raf and A-Raf) that then phosphorylates MEK. Finally the phosphorylation of ERK (1/2) leads to the 
activation of factors involved in cell cycle progression including cyclin D and transcription factors such as ETS 
and myc.  
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1.3 Endoplasmic Reticulum:  
1.3.1 Homeostasis: 
The Endoplasmic reticulum (ER) is a series of double membrane sacks called cisternae 
within eukaryotic cells that bud off the nuclear membrane and remains in proximity to that 
membrane. The ER has several functions including Calcium (Ca2+) storage and the folding of 
newly translated nascent soluble or membrane bound proteins destined for secretion or 
translocation to other organelles within the cell. The ER lumen is a more oxidising environment 
than the cytosol which allows for more efficient folding and maturation of proteins containing 
disulphide bonds (Helenius, Marquardt and Braakman, 1992). A third of all nacsent peptides are 
co- or post-translationally processed in the ER and golgi. Indeed between this and lipid 
membrane production ER homeostasis is vital for the health of the cell. Recently a number of 
key studies have established that disruption of ER homeostasis, can have deleterious effects on 
the organism as a whole giving rise to a variety of pathological conditions many of which are 
linked to dysregulated inflammatory (Mear et al., 1999; Peeters et al., 2004; Romero-Ramírez et 
al., 2004; Casas-Tinto et al., 2011; Sha et al., 2011; Gorasia et al., 2015) 
To undergo folding in the ER proteins, make their way into the ER in a process called 
translocation which can occur during the point of translation (Figure 1.3.A). For a peptide to 
translocate into and translation completed within the ER it requires a N-terminal targeting 
sequence, or ER signal peptide, which is usually about 15-30 amino acids long, that is recognised 
by a signal recognition particle (SRP) as soon as the nascent peptide starts to leave the ribosome. 
This SRP-polypeptide unit, whose translation is temporarily halted due to the docking of the SRP, 
joins with the cytosolic face of the ER at the translocon sec61 complex (Zimmermann, Müller 
and Wullich, 2006). At this point the nascent peptide continues being translated whilst being fed 
into the ER lumen. To complete translation, EDj1 is recruited to sec61, nascent peptides are 
bound to Binding Immunoglobulin Protein (BiP) a polygamous Heat Shock Protein 70 (HSP70) 
chaperone, by an ATP-ADP exchange. At this time up to half of all ER processed peptides can be 
glycosylated by oligosaccharylstransferase, with an oligosaccharide containing mannose units to 
which a glucose molecule is added by UDP-Glucose Glycoprotein Glycosyl Transferase (UGGT). 
Once glycosylation occurs the protein enters into the Calnexin/Calreticulin cycle; the removal of 
mannose from this chain acts as a type of molecular clock the ticking of which causes proteins 
which failed-to-fold correctly to, eventually, enter the ER Associated Degradation (ERAD) 
pathway (Tannous, Pisoni and Hebert, 2015; Qi, Tsai and Arvan, 2017)(Figure 1.3.C/Figure 1.3.E). 
Proteins which have correctly folded are sorted and translocated to their final destinations 
either within the cell or secreted from the cell via secretory vesicles (Figure 1.3.D). 
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 1.3.2 The Unfolded Protein Response: 
On Occasion the ER becomes extremely crowded when there is an accumulation of 
nascent unfolded or misfolded proteins in the ER lumen (Walter et al., 2015). To ease the 
concentration of these proteins the Unfolded Protein Response (UPR) is activated. The UPR is a 
term used to encompass a conserved eukaryote cellular signalling and response system which 
monitors ER homeostasis. The UPR attempts to recover/promote effective protein folding and 
recently, it has been shown that components of the UPR are also activated when other types of 
more generalized cellular stress are encountered such as hypoxic conditions or oxidative stress 
(Rzymski et al., 2010; Jung-Kang et al., 2017) 
When the ER attempts to restore normal conditions via the UPR does so by a). reducing 
ER protein load, inhibiting general protein translation (Protein Kinase R (PKR)-like endoplasmic 
reticulum kinase (PERK)), b). increasing the ER’s capacity to folding or degrade newly synthesized 
or misfolding proteins by increasing ER size and chaperone expression (Inositol Requiring 
Enzyme 1α (IRE1α) and Activating Transcription Factor (ATF6)), and c). removing misfolded 
protein intermediates by induction of Endoplasmic-reticulum-associated protein degradation 
(ERAD) components (IRE1α and ATF6). If ER homeostasis is not successfully returned, the cell 
Figure 1.3: Overview of a Healthy ER. Image adapted from Araki and Nagata, 2011:  The pathways involved 
with the Translocation (A and B), Folding (C), retrotranslocation (D) and finally, potentially the ER associated 
degradation of unfolded or misfolded proteins (E). 
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will undergo apoptosis via ER stress pathway induced mechanisms activated by C/EBP 
homologous protein (CHOP) which is controlled by ATF4 translation, long-term activation of 
XBP-1 and IRE1-JNK signalling pathways which are independent to CHOP (Kato et al., 2012). 
It has been shown recently that the fate of the cell during ER stress is determined by the 
order and timing of UPR component activation events rather than distinct swap of pathways 
(Walter et al., 2015) with early activiation and inhibition of IRE1α/XBP-1 promoting cell survivial 
while early activiation of PERK/eIF2a promotes apoptosis.  
The UPR is thought to be activated by the dissociation of BiP from the luminal surface 
of three major effector proteins, the transcription factor ATF6 and two protein kinases: IRE1α 
(Calfon et al., 2002) and PERK (Figure 1.4). It has been shown that the dissociation of BiP from 
the UPR effectors occurs when the levels of free BiP drop because of an overload of unfolded 
protein although it is thought this might not be the whole story as X-Ray crystallography shows 
dimerised IRE1α contains an MHC fold as the luminal face. This MHC fold seems to allow for a 
finer control over the dimerization of the IRE1α but also seems to lead to (Bertolotti et al., 2000; 
Marciniak and Ron, 2006; Gardner and Walter, 2011) oligomerisation. The dimerised IRE1α self-
activates and acquires a sequence specific RNAse enzymatic activity after autophosphorylation 
of the C-terminal kinase domain at S724 (Hetz et al., 2011)The IRE1 RNAse domain then splices 
an intronic sequence from the mRNA that encodes for a potent bZIP transcription factor known 
as X-box binding protein 1 (XBP-1). This action removes a 26bp unit that contains a stop codon 
that prevents the true bZIP protein being produced in normal conditions (Figure 1.4). The 
spliced(s) XBP-1 (XBP-1s) then upregulates the transcription of genes containing the Unfolded 
Protein Response Element (UPRE (CAGCGTG)) within their promoters (Mori et al., 1992). Finally, 
the oligomers of IRE1α can perform Regulated IRE-1 Dependent Decay of mRNA (RIDD) that has 
been shown to lead to a pro-apoptotic signal via RIG-1 (Maurel et al., 2014; Lencer et al., 2015).  
Like IRE1, PERK also dimerises and activates the kinase by autophosphorylation at the 
kinase domain at T981. The activated PERK kinase phosphorylates eIF2α preventing the 
separation of eIF2β from eIF2α sequestering it away preventing the entire eIF2 subunit from 
being recycled reducing its ability to translate the majority polypeptides produced by the cell 
and subsequently lowering ER protein load (Clemens, 2001). However, this sequestration leads 
to the increased translation a subset of stress response transcripts such as the active ATF4 
transcription factor because ATF4 contains two upstream open reading frames (uORF) that are 
bypassed when eIF2 initiated translation is blocked (Figure 1.4) (Vattem and Wek, 2004; Jackson, 
Hellen and Pestova, 2010). The active ATF4 in turn upregulates the transcription of ATF6, CHOP 
and HERP. As part of this regulatory loop ATF4 also upregulates the production of GADD34 which 
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acts to dephosphorylate eIF2α leading to the reactivation of general translation. This occurs both 
in resolution and apoptosis (Han et al., 2013). Finally, PERK activates Nrf2 (Oxidative response 
bZIP transcription factor) by phosphorylating Nrf2 allowing it to dissociate from its repressor 
Keap  (Figure 1.4). 
The UPRE motif is found within promoters and that is recognised by XBP1. This allows 
those genes containing it to bypass the dampening of translation caused by the phosphorylation 
of the α subunit of the Eukaryotic Translation Initiation Factor (eIF2), a major component of 
ribosomes, by PERK. Such genes include BiP, EDEM, ErDj3-5, GP94, PDI-5 and XBP1 itself (Lee, 
Iwakoshi and Glimcher, 2003).  
ATF6 is a transcription factor that targets the ER Stress Response Element (ERSE) motif 
(CCAAT(N9)CCACG) in the promotor sequences of chaperone genes (Roy and Lee, 1999). When 
BiP dissociates from ATF6, the intact ATF6 translocates to the Golgi where it is cleaved by two 
Golgi resident proteases and the active form travels to the nucleus allowing specific genes, such 
as extra Calnexin and Calreticulin as well as XBP-1 and the lipid synthesis transcription factor 
SREBP2, to be transcribed (Okada et al., 2002).  
 
Figure 1.4: Overview of the Unfolded Stress Response. Adapted from Brown & Naidoo, 2012: The 
dissociation of BiP from the luminal surfaces of the three transduction proteins, PERK, IRE1 and ATF6, leads to 
the Unfolded Protein Response. IRE1 autophosphorylation leads to the translation of XBP-1s and the 
transcription of chaperone and ERAD proteins. PERK autophosphorylation causes the phosphorylation of 
EIF2α which inhibits global translation in favour of UPRE and ERSE containing genes. ATF4 is translated due to 
this inhibition which leads to the translation of CHOP and GADD34. CHOP leads to the activation of apoptosis 
and GADD34 dephosphorylates EIF2α causing re-initiation of global translation in both resolution and 
apoptosis. ATF6, after processing in the golgi body, transcribes a similar cluster of genes as XBP1 included BiP 
ErDj3,4 and 5 and Calnexin/Calreticulin. 
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As with MIF the UPR does, eventually, talk to mTORC1 and mTORC2 via the suppression 
of TSC1/TSC2 due to the suppression of ATF6, which leads to the modulation of UPR downstream 
effects as it has been recently shown that mTOR does in fact affect UPR output; most notably 
apoptosis and autophagy but also it has been implicated in B-Cell maturation (Appenzeller-
Herzog and Hall, 2012). mTOR performs a similar function to the UPR, that of keeping the cell 
alive. However, mTORC1 works in opposition to the UPR, by causing more protein production 
due to phosphorylating 4E-BP1, by activating antioxidant pathways and turning on 
gluconeogenesis. This being said, mTORC1 also reinforces the lipogenesis signal given by the 
UPR as well as IRE1-JNK pathway and the apoptotic signal that is provided in chronic ER stress 
as well as the UPR providing more activation potential by ATF6 and CHOP induced AKT activation 
(although this is cancelled out by IRS1 and mTORC2 in chronic cases) (Appenzeller-Herzog and 
Hall, 2012).  
1.4 Cross talk between MIF and the UPR: 
Despite sharing downstream targets including NF-κB and mTOR, it is not known whether 
MIF can directly affect the UPR signal transducers PERK/ATF4 and IRE1α/XBP1. There are a few 
crossover points between the MIF signalling pathways and the UPR, including JNK. However, 
because of these shared downstream targets it is possible that MIF may cause modifications to 
the standard UPR such as causing the cells to be held in autophagy rather than advancing onto 
apoptosis.  
2.0 Aims: 
 The aim of this project is to, using chimeric fluorescent proteins transfected into two 
different cell lines HeLa and SH-SY5s, detect whether the application of MIF causes changes to 
the initial signal transduction components of the UPR, PERK (ATF4) and IRE1 (XBP1), by co-
administering MIF and the UPR inducer Thapsigargin. To perform these experiments chimeric 
UPR reporter constructs ATF4(1-28).EYFP and XBP-1.EYFP and SH-SY5Y reporter cell lines 
produced by Prehn lab (Walter et al., 2015) were obtained and characterised. In addition, 
isogenic HeLa cell clones transfected with the ATF4 reporter construct were also produced and 
characterized. The results of the UPR reporter cell line experiments were followed by 
transcriptional analysis of several downstream targets of the UPR using RT-qPCR.  
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3.0 Methods and Materials: 
3.1 Bacterial Culture: 
Escherichia coli strains were maintained LB broth (24% tryptone, 12% yeast extract, 
24% NaCl) or LB agar (LB broth with 4% w/v agar) with the appropriate antibiotic selection 
(kanamycin 100 g/mL). For long term storage the bacterial cultures were stored at -80° in a 
20% glycerol stock.  
3.1.1 Transformation of E. coli:  
The UPR reporter plasmids Human p.ATF4/XBP1.YFP-N1, were transformed into 
chemically competent Top10 using a modified rubidium chloride -based protocol (Inoue et 
al.,1990). 
Top10 were inoculated either directly from frozen stocks or from an overnight LB agar 
plate 5mls of LB broth is inoculated overnight at 37°C. The following day re-suspend 1.5ml of the 
overnight in 125ml 2xYT (52% tryptone, 32% yeast extract, 16% NaCl). This is incubated in a 
shake incubator at 37°C until culture reaches an OD600 0.5-0.7. The culture is pelleted by 
centrifuging 5000 rpm for 10 minutes at 4°C. Keeping the cells on ice, the pellet is resuspended 
in 70ml RF1 solution (RF1 100mM RbCl, 50mM MnCl2, 30mM KOAc, and 10mM CaCl2, 15% w/v 
glycerol, pH5.8). Gently resuspend the cells and incubate on ice for 1 hour. Recentrifuged in 
previous conditions. Still keeping the cells on ice, resuspend the pellet, removing all the clumps, 
in 20ml RF2 solution (10mM MOPS, 10mMRbCl, 75mM CaCl2, and 15% w/v glycerol)). Take pre-
cooled (-80°C best) cryo-vial tubes aliquot Bacteria and freeze in liquid nitrogen. These are then 
stored at -80.  
3.1.2 Transformation: 
   These chemically competent bacteria were transformed with the plasmid of choice via 
heat-shock. To perform heat-shock transformation this the procedure used was this: The frozen 
aliquot was removed from the -80C and the competent cells thawed and kept on ice. A plasmid 
DNA that is a maximum of 10% of bacterial volume (10µl in 100µl) is added (dependent on 
plasmid concentration) and is kept on ice for a minimum of 10 minutes. The aliquot is then 
placed in a 42° water bath for exactly 45 seconds and immediately placed back on ice for 5 
minutes. At the end of five minutes 350µl of LB or 2 x YT broth is added to the aliquot and then 
incubated at 37 degrees for an hour to help the recovery of the now transformed bacteria. The 
transformed bacteria were spread on LB agar plates containing the appropriate selection 
antibiotic and are left overnight in a 37oC Incubator. 
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3.1.3 Mini/Midi plasmid prep:  
Plasmids were purified from transformed bacteria grown overnight in a minimum of 5mls or 
a maximum of 100mls of LB broth with the appropriate antibiotic. The plasmid extraction was 
then performed using Qiagen’s mini or midiprep system according to manufacturer’s protocols 
with the modifications below. Minipreps are used for small extractions, approximately hundred 
nanograms of plasmid, compared to midiprep from which a yield of one microgram or more of 
plasmid can be expected. The minipreps were performed according to manufacturer’s protocol 
(Qiagen). The midipreps were also performed according to the manufacturer’s protocol, but 
with a change to the post P3 wash centrifugation step, spinning once at 25000 rpm for 30 
minutes (Qiagen).  
3.2: The UPR reporters:   
 The two UPR reporter constructs, pATF4.EYFP-N1 and pXBP1.EYFP-N1, are derivatives 
of the pEYFP-N1 Plasmid (Clonetech). These were made and donated for this study by F. Walter 
and JHM Prehn’s (Walter et al., 2015). pEYFP-N1 contains the Enhanced Yellow Fluorescent 
Protein driven by a CMV promoter. Also contained within the pEYFP-N1 is a 
neomycin/kanamycin cassette for resistance in both Bacteria and mammalian cells (Figure 
3.1)The ATF4.eYFP was created using 280bp of the 5’ UTR immediately upstream of the 
coding region and 84 bp coding for the first 28 amino acids of Human ATF4. It was cloned 
and the restriction sites XhoI and HindIII was added to allow for cutting into the MCS of 
the pEYFP. (Figure 3.1.A). The pXBP-1.EYFP-N1 is the full Human pre-splicing transcript of 
XBP-1 including the splice site and the DNA Binding Domain. The cloned XBP1 was 
inserted into the pEYFP-N1 plasmid between the XHOL and HindIII cutsites within the 
Multiple Cloning Site (Figure 3.1.B)  
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Figure 3.1: Schematic of the Reporter Plasmid pEYFP-N1 (A) This is the complete ATF4.EYFP-N1, 
the 360bp insert is between XhoI and HindIII allowing the mRNA to be produced that over runs into 
the eYFP cassette. (B) This is the complete XBP-1.EYFP-N1. To make this it has the full human which 
is inserted between XhoI and HindIII allowing the mRNA to be produced that includes the eYFP 
cassette plus a small linker.  
 
A 
B 
15 
 
The ATF4.eYFP reporter 5’ UTR contains two ORFs that in eIF2α-rich environment are 
translated in succession because of the quick reacquisition of the ribosome after the end of the 
uORF1. This does not occur in ER stress conditions, the reacquisition of the 60s component and 
eIF2 only occurs once it has reached the ORF3 and the protein is translated (Figure 3.2.A).  
The XBP1.YFP construct works by IRE1α’s RNAse removing a 26nt segment from the 
mRNA that removes the stop codon from the intron that prevents full translation of XBP1 from 
occurring (figure 3.2.B).
uORF2 Stop Codon 
EYFP 
 
UPR conditions 
1-28aa 
ATF4
  
5’UTR ORF 1/2 
Figure 3.2: Activating Transcription Factor 4 and X-Box Binding Protein 1 ER Stress reporters constructs: 
(A) ATF4.EYFP reporter: This has two upstream Open Reading Frames (uORFs) that control translation that exist within the 5’ 
untranslated region. uORF2 contains a stop codon that is read when Eukaryotic Initiation Factor 2 (eIF2α) binds to the mRNA 
within ORF2 after completing the uORF1. Due to the phosphorylation that ElF2α undergoes in ER stress conditions this stop is 
not read because of the delay in creating the Holoenzyme, because of the sequestering of ElF and, in vivo, ATF4 is translated. 
This has been taken advantage of and so in the reporter the 5’UTR is attached to YFP via a 28-amino acid linker. 
(B) XBP-1.EYFP reporter: This reporter works by utilising the alternative splicing of XBP-1. When classical splicing of the XBP-1 
mRNA occurs the stop codon present within the splice site prevents translation of the XBP-1.EYFP. Upon alternative splicing by 
IRE1 this stop codon is removed so XBP-1 and Yellow is expressed. This XBP-1 is the full transcript so unlike the ATF4 it does have 
cause downstream effects. 
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Intron 
Exon Exon Splice 
Intron 
EYFP 
Exon XBP-1s 
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3.3 Mammalian Cell Culture and Chemicals:  
 The mammalian cells used in this study are HeLas, Human Embryonic Kidneys 293s and 
SH-SY5s were maintained in complete media (Dulbecco’s Modified Eagles Medium (DMEM) 
supplemented with extra glucose, L-glutamine (Sigma Aldrich) 10% (Hela) or 15% (SH-SY5s) FCS 
(Gibco), 1% Penicillin/ Streptomycin (Sigma Aldrich)) and grown at 37°C and 5% CO2.  Stocks for 
both cell lines were made using 90% FCS/ 10% DMSO (Sigma Aldrich) freeing media and stored 
at -80°C or -170°C.  ER stress was induced by Thapsigargin (Sigma Aldrich).   
3.3.1 Mammalian Transient Transfection: 
To transiently transfect the cells of choice with an experiment specific plasmid, such as 
the p.ATF4/XBP1.EYFP-N1, the JetPrime DNA and siRNA Transfection Reagent was used 
according to manufacturer’s instructions (Polyplus). Cells were counted and seeded at the 
density suggested by the manufacturer instructions. For 24 well plates this is ~ 80,000 cells/well 
but varies depending on well size with a total volume of 0.5 mL of media (Table 3.1). 
 
If the plasmid of choice is wanted to be used at a lower concentration than 
recommended, then a carrier DNA plasmid pUC18 was used to aid the transfection. This plasmid 
is added in an amount per well that makes the difference between optimum and required. An 
example of this is the titration of with the highest level, 0.5µg of with no pUC18 but the lowest 
0.125µg containing 0.375µg of the puc18. After the mixing of the JetPrime buffer and the 
plasmid of choice then it is vortexed and centrifuged in a single speed bench top centrifuge. The 
JetPrime is then added to the plasmid/buffer mix at a set ratio per well (Table 3.2).  
 
 
 
 
 
 Table 3.1: Absolute quantity of DNA and Jetprime used to transfect cells 
Multi-well plate Cells per Well Volume of jetPRIME® 
Buffer  
(μl)  
Total amount of DNA  
(μg)  
24-well  1*105 50  0.5  
6-well 1*106 200  2  
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After the addition of the Jetprime the sample was vortexed, spun once more and then 
incubated for ten minutes on the bench. After incubation, 50µl of the mixture is added dropwise 
to each well and incubated for a minimum 4 hours before the media is changed and a minimum 
of 16 hours before the cells are either treated with drug or processed for analysis by flow 
cytometry.  
3.3.2: Isolation of Mammalian Cell lines stably transfected with UPR reporters: 
 Transient transfection efficiencies can vary between experiments and can create 
heterogeneous populations of transfected cells which express different levels of the reporter 
constructs. To try and overcome some of these experimental limitations we attempted to 
isolate stable cell lines harbouring XBP-1 and ATF4 ER stress reporter constructs. 1x106 cells 
were seeded per well in a 6 well plate and transfected with X amount of reporter construct 
made up to a total of 2 g with the carrier DNA. Transfected cells were grown in selection free 
media overnight and then transferred into containing media, G418 (50µg/ml), and grown 
under selection. Untransfected control cells were used to monitor the activity of the G418 and 
ensure transfected cells growing through the selection were genuine transfectants. 
Transfected polyclonal cell lines were expanded under selection, assessed in the ER stress 
response assays and frozen stocks made in freezing media (90% FCS, 10% DMSO).3.3.3 
Isolation of Single Cell Clones:  
To isolate isogenic stably transfected clones for each construct the polyclonal cell lines were 
diluted to a concentration of 0.5 cells/mL and 200 L added to each well of a 96 well plate. Cells 
were grown in selection for a minimum of two weeks until islands of growth could be observed. 
Clones were then expanded, assessed in the ER stress response assays and frozen stocks made 
in freezing media.  
  
Table 3.2: The Concentration of JetPrime Reagent 
Multi-Well Plate Volume of jetPRIME® Reagent (μl)  
96-well*  0.2 - 0.3  
24-well  1 - 1.5  
12-well  1.6 - 2.4  
6-well / 35 mm  4 - 6  
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3.4 Flow Cytometry:  
To assess the activity of the ER stress reporter constructs of cells were trypsinized, 
washed and resuspended in ~350µl of FACS sheath. Levels of cell fluorescence were measured 
using a FACScelesta (BD Bioscience) with a set gating strategy for each fluorescent marker. For 
time point experiments the cells were fixed in 3.8% Paraformaldehyde (PFA) 10 minutes then 
washing 3x in 1xPBS and refrigerated before analysis. FACS data was acquired on Diva (BD 
Bioscience) and analyzed on FlowJo (BD Bioscience).  
3.4.1 Specific Experiment Set Ups: 
For most experiments, cells were seeded into a 24 well plate at a concentration of 
1x105 cells /well in G418 containing media between 16 and 24 hours before being treated with 
150 nM of TPG and/or 250ng/ml of human MIF1 (kindly donated by M.Neville, Guiliano Lab). 
To test the assess of MIF alone on the reporter constructs cells were treated with a range 
31ng/ml - 1500ng/ml of MIF. 150nm TPG as a standard ER stress activation control. Within 
most experiments all conditions used had three experimental replicates. Most experiments 
were repeated a minimum of two times. The fluorescence of cells was assessed by FACS at 8 
hour and 16 hrs post treatment.  
For the time course experiments the standard times analyzed for both constructs were 
4, 6, 8, 12, 16 and 24 hours post treatment with the additional timepoints of 36 and 48hrs 
post-treatment were used for the ATF4 reporter.  
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3.5 RNA Extraction, Reverse Transcription and Quantitative PCR: 
3.5.1 RNA Extraction:  
For total RNA extraction 2.5x105 isolated cells were stored in 200-300µl of RNAlater 
(ThermoFisher) at -20 until ready to extract using the Isolate II kit (Bioline). Extractions were 
performed using manufacturer’s protocol. Briefly after diluting the RNAlater and cells with 100ul 
of PBS the cells were lysed by the addition of 350µl RLY buffer, 3.5µl β-Mercaptoethanol. The 
lysate was then applied into the isolate II filter and centrifuged for 1 minute at 11000 RCF to 
remove cellular debris. The 350µl of 70% ethanol is added to the supernatant to allow binding 
to the column and is mixed by pipetting or vortexing. The lysate solution was then added to the 
binding column, total volume is 750µl, and centrifuged for 30s at 11000 RCF. 350µl membrane 
desalting buffer was added to the column and after a 30s centrifugation the DNAse I solution 
was applied and incubated at room temperature for 15 minutes. To stop the activity of the 
DNAse I, RW1 wash buffer was added to the membrane and then centrifuged for 30s at 11000 
RCF. The column was then washed with 600µl RW2 and 250µl RW2 buffer. Finally, 60µl of RNAse 
free water is added to the column, whilst on ice, and allowed to permeate the membrane for 5 
minutes before centrifugation at 11000 RCF for 1 minute to elute the RNA.  
3.5.2 Reverse Transcription:  
First strand cDNA was synthesized using the SensiFAST cDNA kit (Bioline) and the 
manufacturer’s protocol: X-X ug of total RNA was used.  
 
Table 3.3: The concentration of RT-PCR reagents 
Total RNA or mRNA (up 
to 1 μg)  
n μl (15μl total) 
5x TransAmp Buffer  4μl  
Reverse Transcriptase  1μl  
DNase/RNase free-
water*  
Up to 20 μl  
 
After gently vortexing and centrifugation the samples were placed in the thermocycler 
(Bio-Rad) and the 1st strand cDNA was synthesized using the following cycling conditions: 25 °C 
for 10 min, 42 °C for 15 min, 85 °C for 5 min and finally 4 °C indefinite hold. cDNA can be stored 
at -20°C for long term storage.  
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3.5.3 Quantitative PCR: 
qPCR was performed using the the Bioline SensiFast SYBR High-ROX kit and an AriaMx 
cycler and analysed on the Mx 1.6 Software (Agilent). Primers for CHOP (5′-
GGTCCTGTCTTCAGATGAAAATG-3′; 5′-CTTGGTGCAGATTCACCATTC-3’) and ErDj4 (5′-TGGCCATG 
AAGTACCACCCTGACAA-3’; 5′-TCCACTACCTCTTTGTCCTTTACCACT-3’) were taken from Walter et 
al., 2015. The house keeping gene  GAPDH was used as the control for normalization of the 
results. The GAPDH primers set were designed using the NCBI Primer-Blast tool 
(https://www.ncbi.nlm.nih.gov/tools/primer-blast/). 
To perform the qPCR the cDNA from the previous RT step must be normalised to the 
lowest concentration of RT products, but recommended no lower than 100ng (as determined 
by concentration added to the RT reaction). Ten μl of the Sensifast kit 2x premade mix (Mg2+, 
polymerase, SYBR green and ROX) was added to 1μl of each primer and up to 4μl of cDNA per 
reaction for a total volume of 20μl.  
The reaction plate was loaded with the master mixes for each gene, to which the 
template or control RNA was added no Template and no RT Controls were performed for each 
set of reactions, After the plate is loaded with template and RNA, it was sealed with a plastic 
film to prevent evaporation, centrifuged for a 1 minute at 1500rpm to remove air bubbles and 
placed into the cycler to run through the program. The following cycling conditions were used: 
95°C for 2 min, 95°C for 5 sec 60°C for 10 second. After 40 cycles of this 2-step program a melt 
curve was performed by reading the fluorescence every 0.5°C between 95°C and 60°C and 
back to 95°C. to check the uniformity of products produced during the PCR. 
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4.0 Results: 
Three commonly used laboratory human cell lines HeLa, Human Embryonic Kidney 293 
(HEK 293), and SH-SY5Y (neuroblastoma) were selected for the assessment of MIF treatment on 
ER stress responses. After initial attempts to optimize transfection of reporter constructs were 
completed further it was decided to abandon further work with HEK293 cells as there were 
inconsistencies in responses observed with both the XBP-1.pEYFP-N1 and ATF4.pEYFP-
N1reporter constructs and it was not possible to isolate either polyclonal or isogenic clones 
during the timeframe of the project (see appendix supplementary data and figures S1 and S2). 
4.1 Optimization of transfection of the ER stress constructs into HeLa cells:  
ER stress reporter plasmid constructs XBP-1.pEYFP-N1 and ATF4.pEYFP-N1 received 
from J.M Prehn lab (Walter et al., 2015) were transiently transfected into the HeLa cells after 
they were seeded into 24 well plates (Figures 4.1 and 4.2). To identify optimal transfection 
conditions each construct was titrated into the cells with DNA concentrations ranging from 
0.125 - 1µg of DNA per 1x105 cell were left for 24 hours to allow reporter expression and their 
mean florescent intensities measured at 16 hrs after treatment with 150nM Thapsigargin 
(TPG).  
  HeLa cells were successfully transfected with the XBP-1 reporter construct and at 16 
hours the HeLas (Figure 4.1) showed a consistent titration dependant response to a fixed dose 
of TPG. After TPG treatment there is an increase in the number of the eYFP positive cells 
relative to the vehicle transfected cells. The MFI of the positive cells (Figure 4.1.D) for both 
untreated and treated increases between 0.125µg and 0.25µg then plateaus after 0.25µg. It is 
of note that the maximum MFI never reaches beyond 250 AU in any conditions tested. We 
speculate this may be a result of toxic or auto-regulatory effects of the XBP-1.eYFP fusion 
protein.  
Analysis of the kinetics of the ER stress reporter constructs was performed by 
monitoring eYFP levels in 150nM TPG treated HeLa cells over a 24 hr (XBP1) or 36 hr (ATF4) time 
course. For the XBP-1.pEYFP-N1 reporter there was a steady increase in the number of eYFP 
positive cells (5 to 25%) peaking at 16 hrs post treatment (Figure 4.2.B). However, while there 
was a clear and sustained increase in the number of eYFP positive cells there was only a transient 
increase in the MFI of eYFP positive cells (~2x untreated cells) that peaked 8 hr post treatment 
with TPG (Figure 4.2.D).   
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Figure 4.1: Optimisation of HeLa Cells Transiently Transfected with Different Doses of 
XBP1.eYFP Transcriptional Reporter. HeLa cells were seeded 24 hrs before transfection with the  
XBP-1.pEYFP-N1 reporter construct and treatment with 150 nM TPG. Sixteen hours after 
treatment cells were collected fixed and analysed by FACS. (A) Intact cells gate was set on the 
dot plot.  Intact cells were then assessed for levels of eYFP. (B) The eYFP positive gate was set so 
that less than 0.1% of the untransfected cells fell within the gate. The histogram shows 
representative results using 0.25 ug reporter DNA/105 cells. (C) The graph shows the percent of 
eYFP positive cells 16hrs after treatment with TPG in Hela cells transfected with a range of  
reporter plasmid DNA concentrations (ranging 0.125- 1µg DNA/5x104 cells, UT: Untransfected 
cells). (D) The changes in the MFI of the eYFP positive cells is also shown (N=1).     
A B 
C D 
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Untransfected 
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Figure 4.2: The Activation of the XBP-1.eYFP Transcriptional Reporter over Time in HeLa cells 
after  Treatment with TPG. Hela cells were seeded 24 hrs before transfection with 0.5 µg/1x105 
cells the  XBP-1.pEYFP-N1 reporter construct and treatment with 150 nM TPG. Cells were 
analysed by FACS 2, 4, 6, 8, 12, 16 and 24 hours post-treatment. Intact cells were assessed for 
levels of eYFP expression. (A) The eYFP positive gate was set so that less than 0.1% of the 
untransfected cells fell within the gate. (B) The change in percent eYFP positive cell. (C) These 
cell’s MFI was assessed in TPG treated cells over a 24 hour time course (N=1). 
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HeLa cells were also transfected with ATF4.pEYFP-N1 (Figure 4.3). However, while there 
was correlation between the amount of DNA transfected into the cells and the number of eYFP 
positive cells this was not consistent with changes in the MFIs of the cells after treatment with 
TPG (Figure 4.3.C and D). The only exception to these observations were the cells transfected 
with 0.125 µg DNA per 1x105 cells. These cells showed both an increase in the number of eYFP 
positive cells and MFI of eYFP positive cells after TPG treatment (Figure 4.3C and D). 
The ATF4.pEYFP-N1 reporter construct showed a bimodal peak in the percent of eYFP 
positive cells over the 36 hour time course at 4 and 18 hrs post-treatment increasing from 15% 
(0) to 55% at (18 hrs) post-treatment (Figure 4.4.B). The MFI of the eYFP positive cells also 
peaked 18hrs post-treatment (Figure 4.4.D).  
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Figure 4.3: Optimisation of HeLa Cells Transiently Transfected with the ATF4.YFP 
Transcriptional Reporter. HeLa cells were seeded 24 hrs before transfection with the  
ATF4.pEYFP-N1 reporter construct and treatment with 150 nM TPG.  Sixteen hours after 
treatment cells were collected fixed and analysed by FACS. (A) Intact cells gate was set on the 
dot plot.  Intact cells were then assessed for levels of eYFP. (B) Intact cells were assessed for 
levels of eYFP. The eYFP positive gate was set so that less than 0.1% of the untransfected cells 
fell within the gate. The histogram shows representative results using 0.25 ug reporter DNA/105 
cells. (C) The graph shows the percent of eYFP positive cells 16hrs after treatment with TPG in 
HeLa cells transfected with a range of  reporter plasmid DNA concentrations (ranging 0.125- 1µg 
DNA/5x104 cells, UT: Untransfected cells).  (D) The changes in the MFI of the eYFP positive cells 
is also shown  (N=1). 
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Figure 4.4: The Activation of the ATF4.eYFP Transcriptional Reporter over Time in HeLa cells 
after Treatment with TPG. HeLa cells were seeded 24 hrs before transfection with 0.5 µg/5x104 
cells the  XBP-1.pEYFP-N1 reporter construct and treatment with 150 nM TPG. Cells were 
analysed by FACS 2, 4, 6, 8, 12, 16, 24 and 36 hours post-treatment. Intact cells were assessed 
for levels of eYFP expression. (A) The eYFP positive gate was set so that less than 0.1% of the 
untransfected cells fell within the gate. (B) The change in percent eYFP positive cells and (C) their 
MFI was assessed in TPG treated cells over a 24 hour time course (N=1). 
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4.2: Assessment and Characterisation of Stably Transfected SH-SY5Ys:  
Upon receipt of the monoclonal SH-SY5Y ER stress reporter cells from the Prehn lab 
(Walter et.al 2015) they were tested to determine their sensitivity and specificity to ER stress 
inducers after storage and transport. This was performed by seeding the cells into a 24 well 
plate, at 5x104 cells/well, then 24 hours later treating them with 375nM, 750nM, 1500nM or 
3000nM TPG. The rational for testing doses of TPG within this range for the SH-SY5Y was based 
on the previously published working concentration used by Walter et al. (2015) and it was not 
known if the cells would respond to lower concentrations of this drug. 
The cells were harvested and fixed with 3.8% PFA  8 hours after TPG treatment. Wildtype 
SH-SY5Ys were used as controls to set the gates for intact and eYFP positive cells. The SH-SY5Ys 
did not fix particularly well, leading to lower numbers of intact cells when compared to HeLa 
cells (data not shown).  
While the ATF4.eYFP-N1 transfected SH-SY5Y monoclonal cell line (subsequently 
referred to as WATF4-SH-SY5Y)  responded all the doses of TPG with an increase both the 
percent of eYFP expressing cells and the MFI after treatment (Figure 4.5.B and C) there was no 
clear dose responsiveness in the conditions tested (Figure 4.5.B). Based on this initial data it was 
decided that in future experiments 150nM of TPG would be used for the next series of 
experiments to minimize toxicity and provide  similar experimental conditions used with the 
HeLa cells and in subsequent RT-qPCR assays. However, examination of FACS results of the cells 
treated with 3mM TPG indicates that this concentration was potentially used  in  Walter et. al.  
because it activates apoptotic pathways in these cells (Figure 4.5.C).  
Unfortunately, the  XBP-1.eYFP-N1 transfected SH-SY5Y cells provided by the Prehn lab 
(subsequently referred to as WXBP1-SH-SY5Y), did not respond well to any concentration of TPG 
tested (Figure 4.6.B and C) the cells showing a 0.5% increase in eYFP positive cells (Figure 4.6.B). 
In light of these difficulties wild-type SH-SY5Y were transfected with the XBP-1.eYFP-N1 plasmid 
and a new polyclonal line containing this reporter construct isolated in parallel with the isolation 
of  a HeLa polyclonal cell line transfected with the same construct.   
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Figure 4.5: Assessment of Sensitivity and Specificity of the WATF4-SH-SY5Y Reporter Cell Line. 
Cells were seeded and allowed to recover for 24 hrs before treatment with a range of 
concentrations of TPG. Cells were collected fixed and analyzed by FACS 16 hours after treatment. 
Intact cells were assessed for levels of eYFP. (A) The eYFP positive gate was set so that less than 
0.1% of the untransfected cells fell within the gate. (B) The changes in percent eYFP positive cells  
and (C) their MFI was assessed over drug titration series.  While the cells responded well to TPG 
there was no correlation between drug concentration and the number of eYFP positive cells or 
their MFI (N=1). 
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Figure 4.6: Assessment of Sensitivity and Specificity of the WXBP1-SH-SY5Y Reporter Cell Line. 
Cells were seeded and allowed to recover for 24 hrs before treatment with a range of 
concentrations of TPG. Cells were collected fixed and analyzed by FACS 16 hours after treatment. 
Intact cells were assessed for levels of eYFP. (A) The eYFP positive gate was set so that less than 
0.1% of the untransfected cells fell within the gate. (B) The changes in percent eYFP positive cells 
and (C) their MFI was assessed over drug titration series. The WXBP-1-SH-SY5Y reporter cell line 
did not show significant responses to TPG and there was no correlation between drug 
concentration and the number of eYFP positive cells or their MFI  (N=1).  
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4.3: Isolation of Polyclonal and Isogenic ER Stress Reporter HeLa and SH-SY5Y Cell 
Lines: 
After performing our initial studies in both the HeLas and the SH-SY5Y cells it was 
decided that new stably transfected cell lines were required to improve the consistency of the 
data so both cell lines were transfected with the XBP-1.pEYFP-N1 and ATF4.pEYFP-N1 reporters 
and polyclonal lines selected using G418. Once stable polyclonal lines were isolated, we 
attempted to further isolate isogenic clones for each cell line and construct.  
4.3.1: Isolation of Polyclonal HeLa and SH-SY5Y ER Stress Reporter Cell Lines:  
A polyclonal HeLa cell line transfected with the ATF4.eYFP-N1 reporter was successfully 
isolated and subsequently used to produce an isogenic monoclonal cell line harbouring this 
construct (Figure 4.7). 
 However, it was not possible to isolate an equivalent stable polyclonal cell line 
transfected with the XBP-1.eYFP-N1 reporter construct. HeLa cells transfected with this reporter 
either did not survive G418 selection, did not show consistent or high levels of EYFP expression 
or lost expression of EYFP during long term culturing. Fortunately, the SH-SY5Y cells transfected 
with the XBP-1.eYFP-N1 reporter were able to survive G418 selection and responded to TPG 
treatment.  
Producing a stable polyclonal HeLa cell line stably expressing the XBP-1.eYFP-N1 proved 
extremely problematic initial attempts (Figure 4.8) resulted in a polyclonal cell line (ASXBP1-
HeLa-PC1) which showed no activity to the drug. A second cell was made (ASXBP1-HeLa-PC2) 
which showed some activity in response to the TPG treatment (Figure 4.8.A). However, it is not 
dose dependant (Figure 4.8.B) and only a small number of cells showed any expression of eYFP 
with the TPG concentrations tested (~8% of intact cells). However, these cells gained expression 
subsequent rounds of passaging where a larger percentage (30-40%) of the cells responded to 
TPG by expressing eYFP (Figure 4.8.D and E). This cell line was used in the subsequent 
experiments testing the effects of MIF on XBP-1 activation but required higher concentrations 
of TPG for clear responses (700nM) when compared to the HeLa ATF4.eYFP-N1 reporter. 
The SH-SY5Y XBP-1.eYFP-N1 polyclonal line (ASXBP1- SH-SY5Y-PC1) responded to TPG 
treatment showing a dose dependant response rising from 17% to 23% eYFP positive cells 
within the intact cell gate (Figure 4.9). Unfortunately, despite several attempts it was not 
possible to isolate isogenic TPG responsive monoclonal lines derived from either the ASXBP1-
HeLa-PC2 or ASXBP1- SH-SY5Y-PC1 polyclonal cell lines.   
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Figure 4.7: Isolation of a ASATF4-HeLa Polyclonal Cell Line. HeLa cells transfected with 
ATF4.eYFP-N1 were selected with G418 for at least three passages The outgrowing resistant cells 
were seeded and allowed to recover for 24 hrs before treatment with a range of concentrations 
of TPG. Cells were collected fixed and analyzed by FACS 8 hours after treatment. Intact cells were 
assessed for levels of eYFP. (A) The eYFP positive gate was set so that less than 0.1% of the 
untransfected cells fell within the gate. (B) The responses to TPG observed in the ATF4-HeLa-
PC1 lines are shown in changes in eYFP positive cells and (C) the changes in the MFI of eYFP 
positive cells (N=1).
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Figure 4.8 Isolation of a ASXBP1-HeLa Polyclonal Cell Line. HeLa cells transfected with XBP-
1.eYFP-N1 were selected with G418 for at least three passages The outgrowing resistant cells 
were seeded and allowed to recover for 24 hrs before treatment with a range of concentrations 
of TPG. Cells were collected fixed and analyzed by FACS 8 hours after treatment. Intact cells were 
assessed for levels of eYFP. (A) The eYFP positive gate was set so that less than 0.1% of the 
untransfected cells fell within the gate. The responses to TPG observed in the ASXBP1-HeLa-PC2 
lines are shown in (B) changes in eYFP positive cells and (C) the changes in the MFI of eYFP 
positive cells. (D and E) ASXBP-1-HeLa-PC2 expressed with more intensity as more passages. 
occurred, the difference between the cells at initial testing and usage (N=1). 
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Figure 4.9 Isolation of a ASXBP1-SH-SY5Y Polyclonal Cell Line.  SH-SY5Ys cells transfected with 
XBP-1.eYFP-N1 were selected with G418 for at least three passages The outgrowing resistant 
cells were seeded and allowed to recover for 24 hrs before treatment with a range of 
concentrations of TPG. Cells were collected fixed and analyzed by FACS 8 hours after 
treatment. Intact cells were assessed for levels of eYFP. (A) The eYFP positive gate was set so 
that less than 0.1% of the untransfected cells fell within the gate. (B) The responses to TPG 
observed in the ASXBP1-SH-SY5Y-PC1 (C) and the changes in the MFI of eYFP positive cells 
(N=1). 
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4.3.2: Isolation and Characterisation of Monoclonal Isogenic HeLa Cells Expressing 
ATF4.pEYFP-N1:  
Isogenic monoclonal Hela cells containing an active ATF4.pEYFP-N1 reporter were 
isolated by taking HeLa cells transfected with ATF4.eYFP-N1 construct, passaging them three 
times under G418 selection and then seeding them into a 96 well plate at ½ a cell per well plate. 
After about two weeks wells with obvious cell growth (colonies) were seeded into indivdual T-
25 flasks and expanded. Ten clones were successfully isolated and tested for the presence of the 
of an active ATF4.pEYFP-N1reporter construct. Most of the clones showed no background eYFP 
expression and no response to TPG (Figure 4.10B and C). However, one clone (D5) showed some 
background eYFP expression and responded to a range of TPG concentrations (150-3000nM) 8 
hrs post treatment (Figure 4.10A). A time-course analysis was performed on this cell line, 
subsequently called ASATF4-HeLa-Isogenic Clone 1 (ASATF4-HeLa-ASATF4-HELA-IC1), using 
150nM TPG which showed that in comparison to the transiently transfected cells (Figure 4.11) 
it had a delay in the peak in eYFP expression (24 hrs vs 16 hrs) and a steady increase in the MFI 
of the cells over the entire timecourse (Figure 4.11). Unlike the transiently transfected HeLa cells 
which have a fluorescence maxima of 104au (Figure 4.3) the ASATF4-HELA-IC1 ATF4 isogenic 
clone (ASATF4-HELA-IC1) shows a narrower range of activation intensities with no fluorescence 
detected above 103au.  
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Figure 4.10: Isolation and Characterization of Single Cell Isogenic HeLa Cells Transfected with 
the ATF4.pEYFP-N1 Reporter Construct. The clones B4, D5 and D9 seeded into a 24 well plate 
and allowed to recover for 24 hrs before treatment with a range of concentrations of TPG. Cells 
were collected fixed and analyzed by FACS 8 hours after treatment. Intact cells were assessed 
for levels of eYFP. (A) The eYFP positive gate was set so that less than 0.1% of the untransfected 
cells fell within the gate. The responses to TPG observed in the three clones are shown in (B) 
changes in eYFP positive cells and (C) the changes in the MFI of the eYFP positive cells (N=1). 
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Figure 4.11: The Activation of the ATF-4.eYFP Transcriptional Reporter over Time in the 
ASATF4-HeLa-IC1 Cell Line after Treatment with TPG. ASATF4-HeLa-IC1 cells were seeded 24 
hrs before treatment with 150 nM TPG. Cells were analysed by FACS 4, 6, 8, 12, 16, and 24  hours 
post-treatment. Intact cells were assessed for levels of eYFP expression. (A) The eYFP positive 
gate was set so that less than 0.1% of the untransfected cells fell within the gate. (B)  The change 
in percent eYFP positive cells and (C) their MFI was assessed in vehicle and TPG treated cell over 
a 24 hour time course (N=3).  
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4.4: Assessment of the Effect on MIF on ER stress responses: 
4.4.1: Assessment of the Effects of MIF on Activation of the ATF.ePYFP-N1 Reporter Cell 
Lines: 
An initial set of experiments was performed to assess the effects of human MIF alone 
on the activity of the ATF4.ePYFP-N1 reporter. To confirm that MIF alone was not able to activate 
the reporter ASATF4-HeLa-IC1 and WATF4-SH-SY5Y cells were treated with a range of MIF 
concentrations and activation of the ATF4.eYFP-N1 reporter measured.  
ASATF4-HeLa-IC1 was seeded in a 96 well plate at a density of 2.5x104 cells per well. 24 hours 
after seeding these cells were treated with a range of MIF concentrations (75ng-1000ng). Cells 
were collected 8 hours post treatment fixed and the levels of eYFP assessed by FACS (Figure 
4.12). A positive control was also performed where cells were treated with 150nM TPG. MIF did 
not cause any consistent effect in levels of background YFP expression in these cells. This 
experiment was repeated were cells were collected at a later timepoint 24 hours post treatment 
to see if these results differed from the 8hr post-treatment timepoint (Figure 4.13). Like the 8 
hr post-treatment cells MIF did not cause any consistent effect in levels of background eYFP 
expression in these cells.  
An equivalent set of experiments was also performed using the WATF4-SH-SY5Y cell line and the  
results for 8 hr post-treatment (Figure 4.14) showed a similar profile to the ASATF4-HeLa-IC1 
cells. This data indicates that in both cell lines tested MIF alone does not significantly affect the 
activation of the ATF4.ePYFP-N1 reporter.  
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Figure 4.12: Assessment of the Effects of MIF on HeLa ASATF4-HeLa-IC1 Cells 8hrs Post-
Treatment. Cells were seeded and allowed to recover for 24 hrs before treatment with a range 
of concentrations of MIF. Cells were collected fixed and analyzed by FACS 8 hours after 
treatment. Intact cells were assessed for levels of eYFP. (A) The eYFP positive gate was set so 
that less than 0.1% of the wild-type control cells fell within the gate. (B) The changes in percent 
eYFP positive cells (C) and their MFI was assessed over range of MIF concentrations tested.  The 
ASATF4-HeLa-IC1 reporter cell line did not show significant responses to MIF No significant 
difference was found between the untreated control and the MIF only titration. Statistical 
analysis for both 4.12.B and 4.12.C determined with One Way ANOVA and Bonferroni Post Hoc 
test for multiple comparisons. (N=3). 
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Figure 4.13: Assessment of the Effects of MIF on HeLa ASATF4-HeLa-IC1 Cells 24 hrs Post-
Treatment. Cells were seeded and allowed to recover for 24 hrs before treatment with a range 
of concentrations of MIF. Cells were collected fixed and analyzed by FACS 24 hours after 
treatment. Intact cells were assessed for levels of eYFP. (A) The eYFP positive gate was set so 
that less than 0.1% of the wild-type cells fell within the gate. (B) The changes in percent eYFP 
positive cells (C) and their MFI was assessed over range of MIF concentrations tested.  The 
ASATF4-HeLa-IC1 reporter cell line did not show significant responses to MIF. No significant 
difference was found between the untreated control and the MIF only titration. Statistical 
analysis for 4.13.B and C was performed with One Way ANOVA and Bonferroni Post Hoc test for 
multiple comparisons (N=3) 
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Figure 4.14: Assessment of the Effects of MIF on WATF4-SH-SY5Y Cells 8hrs Post-Treatment. 
WATF4-SH-SY5Y cells were seeded and allowed to recover for 24 hrs before treatment with a 
range of concentrations of MIF. Cells were collected fixed and analyzed by FACS 8 hours after 
treatment. Intact cells were assessed for levels of eYFP. (A) The eYFP positive gate was set so 
that less than 0.1% of the wild-type control cells fell within the gate. (B) The changes in percent 
eYFP positive cells (C) and their MFI was assessed over range of MIF concentrations tested.  The 
WATF4-SH-SY5Y reporter cell line did not show significant responses to MIF. No significant 
difference was found between the untreated control and the MIF only titration. Statistical 
analysis for both 4.14.B and C was performed with One Way ANOVA and Bonferroni Post Hoc 
test for multiple comparisons (N=3). 
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In a subsequent set of experiments to determine if MIF could influence the activation of  
ATF4 during ER stress conditions cells were co-treated with MIF and TPG and the affects MIF on 
TPG activation of the reporter assessed 24 hrs post-treatment (Figure 4.15). This initial 
experiment did not suggest that MIF had any effect on activation of the reporter at this time 
point. However, because previous studies have shown that the timing and kinetics of the ER 
stress activation response are key factors influencing how it effects downstream processes in 
cells this experiment was repeated in both ATF4.ePYFP-N1 reporter cell lines looking at a time 
course of activation rather than a single time point. 
Within these experiments 250ng/mL  was selected for the MIF dose as this was a median 
dose for the range that had previously been tested in these assays and is a concentration for this 
cytokine that is biologically feasible in vivo.  
The assays performed with the ASATF4-HeLa-IC1 cells showed that MIF treatment 
caused distinct differences in the activation profile of the ATF.ePYFP-N1 reporter (Figure 4.16). 
This encompassed both the number of eYFP positive cells (early time points, <36hrs post-
treatment) and the MFI of the eYFP positive cells (later timepoints, >36hrs post -treatment) with 
MIF suppressing the effects of TPG in these cells. This difference approaches statistical 
significance at p=0.056 (One way ANOVA, n=3).   
The WATF4-SH-SY5Y cells behaved slightly differently while there is no consistent 
difference in the number of eYFP positive cells at later timepoints the MFI of the eYFP positive 
cells is decreased in those cells that were treated with both MIF and TPG (Figure 4.17, n=2). 
However while this trend is promising it does not approach statistical significance when analyzed 
by One way ANOVA. 
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Figure 4.15: Assessment of the Effects of MIF on ASATF4-HeLa-IC1 Cells Treated with TPG 24 
hrs Post-Treatment. ASATF4-HeLa-IC1 cells were seeded and allowed to recover for 24 hrs 
before treatment with a range of concentrations of MIF and 150nM TPG. Cells were collected 
fixed and analyzed by FACS 24 hours after treatment. Intact cells were assessed for levels of 
eYFP. The eYFP positive gate was set so that less than 0.1% of the wild-type cells fell within the 
gate. (B) The changes in percent eYFP positive cells and (C) their MFI was assessed over range of 
MIF concentrations tested.  The ASATF4-HeLa-IC1 reporter cell line did not show significant 
responses to MIF. No significant difference was found between the TPG treated control and the 
MIF and TPG titration. No significant difference was found between the treated time course and 
the MIF and TPG time courses. Statistical analysis for 4.15.B and C was performed with One Way 
ANOVA and Bonferroni Post Hoc test (N=3). 
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Figure 4.16: The Analysis of the Activation of the ATF4.eYFP Transcriptional Reporter over 
Time in ASATF4-HeLa-IC1 Cells after Treatment with TPG and MIF. ASATF4-HeLa-IC1 cells 
were seeded 24 hrs before treatment with 150 nM TPG and 250 ng/mL MIF.  Cells were 
analysed by FACS 2-48 hours post-treatment. Intact cells were assessed for levels of eYFP 
expression. (A) The eYFP positive gate was set so that less than 0.1% of wild-type control cells 
fell within the gate. (B) The change in percent eYFP positive cells and (C) their MFI was 
assessed comparing cells treated TPG and those treated with TPG and MIF. No significant 
difference was found between the treated time course and the MIF and TPG time courses. 
Statistical analysis for 4.16.B and C was performed with One Way ANOVA and Bonferroni Post 
Hoc test (N=3). 
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Figure 4.17: The Analysis of the Activation of the ATF4.eYFP Transcriptional Reporter over 
Time in WATF4-SH-SY5Y Cells after Treatment with TPG and MIF. WATF4-SH-SY5Y cells were 
seeded 24 hrs before treatment with 150 nM TPG and 250 ng/mL MIF.  Cells were analysed by 
FACS 4-24 hours post-treatment. Intact cells were assessed for levels of eYFP expression. (A) The 
eYFP positive gate was set so that less than 0.1% of wild-type control cells fell within the gate. 
(B) The change in percent eYFP positive cells and (C) their MFI was assessed comparing cells 
treated TPG  and those treated with TPG and MIF. No significant difference was found between 
the treated time course and the MIF and TPG time courses. Statistical analysis for 4.17.B and C 
was performed with One Way ANOVA and Bonferroni Post Hoc test (N=2). 
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4.4.2: Assessment of the Effects of MIF on Activation of the XBP1.ePYFP-N1 Reporter 
Cell Lines: 
A similar set of experiments were performed with the ASXBP1-HeLa-PC2 or ASXBP1-SH-
SY5Y-PC1  polyclonal cell lines to assess the effects of MIF alone or MIF in combination with TPG 
on the XBP1.eYFP-N1 reporter. For initial experiments  8 hour post treatment was chosen as the 
timepoint to analyse the effects of MIF on the reporter construct. Like the ATF4.eYFP-N1 
reporter MIF alone does not appear to influence the activation of reporter in either the ASXBP1-
HeLa-PC2 (data not shown) or ASXBP1-SH-SY5Y-PC1 (Figure 4.18) cell lines. However, like the 
ATF4.eYFP-N1 reporter cells time course experiments were performed where the effects of MIF 
and TPG cotreatment on these cell lines was assessed. 
The results of the ASXBP1-HeLa-PC2 time course reveal that unlike the ATF4 reporter 
MIF treatment did not have any effect on the activation of the XBP1.eYFP-N1 reporter in terms 
of the number of eYFP positive cells or their MFI (Figure 4.19). Unlike the HeLa cells analysis, the 
ASXBP1-SH-SY5Y-PC1  cell line shows that like the ATF4 reporter MIF treatment suppresses the 
response to TPG. However, this effect extends into both a reduction of the number of eYFP 
positive cells and the MFI of those cells (Figure 4.19). 
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Figure 4.18: SH-SY5Y Assessment of the Effects of MIF on WXBP1- SH-SY5Y-PC1 Cells 8hrs Post-
Treatment. ASXBP1-SH-SY5Y-PC1 cells were seeded and allowed to recover for 24 hrs before 
treatment with a range of concentrations of MIF. Cells were collected fixed and analyzed by 
FACS 8 hours after treatment. Intact cells were assessed for levels of eYFP. (A) The eYFP positive 
gate was set so that less than 0.1% of the wild-type control cells fell within the gate. (B) The 
changes in percent eYFP positive cells and (C) their MFI was assessed over range of MIF 
concentrations tested.  The ASXBP1-SH-SY5Y reporter cell line did not show significant responses 
to MIF. Insufficient data collected to perform statistical analysis (N=1). 
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Figure 4.19: The Analysis of the Activation of the XBP1.eYFP Transcriptional Reporter over 
Time in ASXBP1-HeLa-PC2 Cells after Treatment with TPG and MIF. ASXBP1-HeLa-PC2 cells 
were seeded 24 hrs before treatment with 700 nM TPG and 250 ng/mL MIF.  Cells were analysed 
by FACS 4-24 hours post-treatment. Intact cells were assessed for levels of eYFP expression. (A) 
The eYFP positive gate was set so that less than 0.1% of wild-type control cells fell within the 
gate. (B) The change in percent eYFP positive cells and (C) their MFI was assessed comparing 
cells treated TPG and those treated with TPG and MIF. No significant difference was found 
between the treated time course and the MIF and TPG time courses. Statistical analysis for 
4.19.B and C was performed with One Way ANOVA and Bonferroni Post Hoc test (N=3). 
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Figure 4.20: The Analysis of the Activation of the XBP1.eYFP Transcriptional Reporter over 
Time in ASXBP1-SH-SY5Y-PC1 Cells after Treatment with TPG and MIF. ASXBP1-SH-SY5Y-PC1  
cells were seeded 24 hrs before treatment with 700 nM TPG and 250 ng/mL MIF.  Cells were 
analysed by FACS 4-24 hours post-treatment. Intact cells were assessed for levels of eYFP 
expression. (A) The eYFP positive gate was set so that less than 0.1% of wild-type control cells 
fell within the gate. (B) The change in percent eYFP positive cells and (C) their MFI was assessed 
comparing cells treated TPG  and those treated with TPG and MIF. No significant difference was 
found between the treated time course and the MIF and TPG time courses. Statistical analysis 
for 4.20.B and C was performed with One Way ANOVA and Bonferroni Post Hoc test (N=3). 
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A 16 hours, Post MIF  
and TPG Treatment 
16 hours, Post TPG 
Treatment 
Untreated 
49 
 
4.5: Assessment of the Effects of MIF on the Downstream Targets of the UPR by 
RT-qPCR: 
To support the results of the transcriptional reporter assays RT-qPCR was performed on 
wild-type HeLa and SH-SY5Y cells examining two downstream targets of the UPR response CHOP 
(ATF4) and ErDj4 (XBP-1). These targets were chosen because their upregulation during ER stress 
encompass the two endpoints for the UPR activation, attempt resolution (ErDj4) or apoptosis 
(CHOP). 
  The results of the RT-qPCR studies of the HeLa cells (Figure 4.21)  partially supports the 
transcriptional reporter assays with MIF reducing the levels of CHOP transcript (a downstream 
target of ATF4) in cells experiencing ER stress relative to control cells (Figure 4.21.A).  Unlike the 
transcriptional reporter assays which did not show any change in XBP-1 activation there was a 
suppression in the levels of ErDj4 transcript which mirrored that of CHOP (Figure 4.21.B).  
In the SH-SY5Y cells a steady decline is seen in the levels of CHOP transcript over the 
time course however this decline is more acute in those cells which had been co-treated with 
MIF and TPG supporting the transcriptional reporter findings in the WATF4-SH-SY5Y cells which 
indicate a suppression of ATF4 activity 12 and 24 hours post-treatment (Figure 4.22.A). Similarly, 
ErDj4 transcript levels drop dramatically after TPG treatment however these partially recover in 
cells by 24 hrs post-treatment (Figure 4.22.B). This recover does not occur in MIF treated cells 
indicating a suppression in XBP activity which is consistent with the lower number of eYFP 
positive cells and lower MFI of eYFP positive cells observed in the transcriptional reporter assays 
using ASXBP1-SH-SY5Y-PC1. 
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Figure 4.21: Assessment of Effects of MIF on CHOP and ErDJ4 Transcript Levels in WT HeLa Cells 
During ER Stress Responses. Wild-type Hela cells were treated with TPG (150nM) or TPG and 
MIF (250ng/mL). RNA was isolated from these cells at 0, 4, 8, 12 and 24 hours post-treatment. 
RT-qPCR was performed using these RNA samples (A) assessing the levels of CHOP (B) or ErDJ4. 
The housekeeping gene GAPDH was used as the internal control to normalise transcript levels. 
The delta-delta Ct of the target transcripts were calculated to determine the relative level of 
each transcript at each timepoint. The relative fold change in gene expression was then 
calculated using the untreated control cells as the baseline level of expression for each 
transcript. No significant difference was found between the treated time course and the MIF 
and TPG time courses. Statistical analysis for 4.21.B and C was performed with One Way ANOVA 
and Bonferroni Post Hoc test (N=1). 
  
CHOP  ErDJ4 
B A 
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Figure 4.22: Assessment of Effects of MIF on CHOP and ErDJ4 Transcript Levels in SH-SY5Y Cells 
During ER Stress Responses. Wild-type SH-SY5Y cells were treated with TPG (150nM) or TPG 
and MIF (250ng/mL). RNA was isolated from these cells at 0, 4, 8, 12 and 24 hours post-
treatment. RT-qPCR was performed using these RNA samples (A) assessing the levels of CHOP 
or (B) ErDJ4. The housekeeping gene GAPDH was used as the internal control to normalise 
transcript levels. The delta-delta Ct of the target transcripts were calculated to determine the 
relative level of each transcript at each timepoint. The relative fold change in gene expression 
was then calculated using the untreated control cells as the baseline level of expression for each 
transcript. No significant difference was found between the treated time course and the MIF 
and TPG time courses. Statistical analysis for 4.22.B and C was performed with One Way ANOVA 
and Bonferroni Post Hoc test (N=1).   
 
ErDJ4 CHOP  
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5.0 Discussion:  
5.1 MIF Partially Suppresses UPR responses: 
A combination of fluorescent protein transcriptional reporter constructs and RT-qPCR 
were used to assess the effects of MIF on UPR induction after TPG treatment in cells derived 
from an epithelial (HeLa) and neuronal (SH-S5Y) lineages. The results of both studies support 
that MIF partially suppresses the induction of UPR responses in both cell lineages.  In both cell 
lines the activity of the ATF4 transcriptional reporter were suppressed while the activity of the 
XBP reporter was supressed in SH-SY5Y cells but not HeLa cells. The RT-qPCR the results obtained 
for the HeLas show a consistent trend from the transduction pathways to the mRNA for the 
downstream targets with a lower mRNA transcription rate for ErDj4 and CHOP. The SH-SY5Ys 
show the same general trend but reasons that are not clear the post-treatment timepoints show 
lower level of ErDj4 and CHOP than the pre-treatment controls .  
5.2: Potential signal transduction pathways that connect MIF UPR activity:  
While a clear transcription effect on UPR in induction was observed in this study the 
defining the molecular mechanisms underlay this effect lay outside the scope of this study. 
However, there are several possibilities. One key regulator of UPR activity that shares common 
signal transduction partners with CD74 mediated MIF signalling is mTORC1. So, one possibility 
is that MIF signalling may somehow impinges on the mTOR pathway in a manner which 
depresses its activation of the UPR.  
A number of recent studies have examined links between these pathways. There is some 
evidence that they are connected, a recent study looking at mTOR knockdown showed that it 
specifically depressed IRE1/XBP activation but not the PERK/ATF4 pathway (Kato et al., 2012). 
Within this study Kato et al., showed that mTOR’s pro-inflammatory/pro-apoptotic activity was 
meditated via modulation of AKT, in which mTOR suppresses the hyperphosphorylation of AKT 
which in turn results in lowers IRE1 activity and suppression of Bcl-2. Similarly, a subsequent 
study showed that inhibition of JNK, a second potential transduction mediator, could link CD74 
mediated MIF signalling caused upregulation of pro-apoptotic signals potentially via activation 
of mTORC1 through activating RAPTOR (Kwak et al., 2012). So, it is possible that one or more 
transduction pathways are influenced by MIF signalling (via CD74) that would modulate 
downstream UPR pathways via distinct activities on IRE1 and mTORC1. This may explain some 
of the slightly different results that were observed between the two cell lines derived from 
epithelial and neuronal lineages.  
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It is known that MIF also has at least one non-classical, CD74 independent, signalling 
route for affecting cells. The most well-known of these non-classical receptors is the intracellular 
target JAB1 (Kleemann et al., 2000). JAB1 can, under a variety of circumstances, phosphorylate 
JNK. However, when MIF binds to JAB1 it inhibits this activity offering another potential pathway 
via which MIF might indirectly influence mTORC1 and UPR transducers such as IRE1. Therefore, 
it reasonable to speculate that suppression of IRE1 caused by MIF might be linked to its activities 
on JAB1. Differences in MIF signalling  via the JAB1 pathway that might be found in different cell 
lineages or differences in a cell’s ability to respond to MIF via CD74 could lead to differences in 
how it influences UPR activation and downstream apoptotic and inflammatory responses.  
Figure 5.1: Diagram showing the Potential Relationships Between MIF and IRE1. Impingement of MIF on 
CD74 leads to an upregulation of mTORC1, this leads to a suppression of AKT leading to a change of IRE1 
from endoribonuclease activity to phosphorylation of JNK. Suppression of JAB1 activity by MIF prevents 
JNK from being phosphorylated leading to a diminished JNK signal and causes a diminished mTOR 
response.  
 Links between PERK/ATF4 and JNK activity have  been identified (Liang et al., 
2006)However, this paper suggests that it is caused by Ca2+ loss within the ER and not by 
blockage of Glycosylation and so it this effect might be an artefact of the use of TPG rather than 
Tunicamycin. This is, of course, undercut by Kato showing that only IRE1 is affected by mTORC1 
activation status. So, cell lineage may also be playing a role as the Kato paper utilized NRK-52E, 
a Rat kidney Epithelial cell line for their study, rather than a human epithelial or neuronal cell 
lineage.  
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5.2: Downstream Targets, E rDj4 and CHOP:  
Due to constraints in the time and scope of the study there are several aspects of the 
RT-qPCR data that is both unexpected and requires further exploration. The effects of TPG on 
CHOP transcript levels in both cell lines showed that there was very little difference between 
the treated and untreated samples in the HeLa cells (Figure 4.19 and 4.20). In addition, 
unexpectedly in  both cell lines the control samples (0 hours) showed much higher levels of CHOP 
transcript relative to the subsequent time points (4-24hrs post treatment). This is possibly due 
to the use of only 150nm of TPG within the treatment so that there was never enough stress 
induced to cause a clear upregulation of CHOP. For ErDj4 there was a more consistent effect in 
the HeLa cells with a clear induction of the transcript after TPG treatment. The results are 
suggestive that MIF suppression mediates effects on both UPR pathways reducing the 
production of both of these key transcripts after ER stress induction however additional assays 
replicating these results and examining additional downstream targets of both XBP-1 and ATF4 
are required.  
5.3: How might MIF Suppression of UPR Influence Health and Disease?:  
This study has identified a potential new role for MIF in modulating UPR during ER 
stress. What ramifications might this have in understanding the potential role of MIF in 
development and disease? Both MIF and ER stress responses have been found to be key 
components in normal homeostatic process and are linked to a variety diseases or disease 
processes. For instance, both MIF and the UPR are linked to disease aetiology in Alzheimer’s 
and Diabetes type 2 (Casas-Tinto et al., 2011, Gorasia et al., 2015). Potential interventions 
based on MIF or UPR targets are being tested in models for both of these diseases. Previously, 
MIF was thought to exert its activity in these diseases by modulating recruitment or activation 
of pro-inflammatory immune cells. However, if MIF differentially suppresses specific elements 
of UPR responses this could potentially lead to apoptosis or pathological responses linked to a 
cells inability to successfully resolve ER dysfunction.  In a recent study published by Walter et. 
al. (2015) the kinetics of activation of the different UPR pathways (IRE1/XBP-1 or PERK/ATF4) 
determined if a cell survived a potentially lethal ER dysfunction. If early IRE1/XBP-1 activation 
and delayed ATF4 translation were cytoprotective and reduced ER stress induced apoptosis. In 
our studies in HeLa cells MIF reduced/delayed PERK/ATF4 activation but did not affect 
IRE1/XBP-1 activity this should allow cells that respond to MIF to survive conditions which 
cause acute ER stress. MIF is found to be produced in high amounts in epithelial tissues like the 
GI tract. Perhaps it helps reduce apoptosis in these tissues when they experience ER stress. 
Interestingly in the SH-SY5Ys (the neuronal cell line) both pathways were suppressed by MIF  
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which could result in the inhibition of resolution of ER dysfunction and promote terminal 
downstream effects. A study recent study has shown that MIF (which is a biomarker for the 
onset of Alzheimer's pathology) exacerbates the toxicity of protein aggregates of beta amyloid 
or tau (Bacher et al., 2010). These aggregates activate UPR responses leading to apoptosis. If 
MIF specifically increases the sensitivity of this cell type to these aggregates this may explain 
why they are selectively lost as the disease progresses and thus why MIF is a biomarker for 
pathology.     
5.5 Future Work: 
There are a number of logical extensions to this study. This would include further 
assessment of the potential downstream targets of MIF, mTOR and JAB1, to see one or both of 
them is required for mediating the UPR suppression. To complete this, XBP-1.eYFP monoclonal 
lines of both HeLa and SH-SY5Ys would need to be isolated. However, due to the potential 
toxicity problems of the full length XBP protein, making constructs that lack the DNA binding site 
from XBP-1 may help facilitate the isolation of stable lines. To make sure the effects of MIF on 
UPR induction are specific a second UPR inducer such as Tunicamycin should also be tested 
within this assay. Once these cells are available the specific pathway that mediates the 
suppression can be examined by either genetically modifying the cells to create JAB1 knockout 
(CRISPR/CAS), or by transiently reducing JAB1 levels using transfection with specific siRNAs. If 
UPR suppression is reduced in the JAB1 deficient cells, then this would suggest that MIF (via 
JAB1) is potentiating IRE1 phosphorylation of JNK. Lastly to confirm and expand results of the 
RT-qPCR data RNA sequencing (RNAseq) should be performed on cell treated with MIF during 
ER stress which will allow simultaneous assessment of transcript levels for a wide variety of UPR 
targets including BIP, Calnexin/Calreticulin, CHOP, EDEM, ErDJ3-5 and GADD34 along with genes 
involved in other biological process such as apoptosis.  
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6.0 Concluding Remarks: 
To conclude, transgenic poly and monoclonal cell lines were produced that show the 
activation of different UPR pathways during ER stress by upregulation of a fluorescent reporter 
proteins. These were tested to assess whether MIF can affect basal levels or Thapsigargin-
induced ER Stress. The fluorescent reporters indicated a MIF suppressed UPR activation 
although there was variation in which UPR pathways that were affected in different cell types.  
These observations were supported by RT-qPCR of specific UPR target transcripts though 
further work is required. This effect, if more advanced work supports it, may be important for 
understanding the aetiologies of a number of conditions where both MIF and ER stress are 
implicated as factors influencing disease development and/or pathology. It might also offer 
potential targets for the development of novel therapeutics strategies for the treatment of 
these diseases.  
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Appendix:  
Figure S1: Optimisation of HEK 293 Cells Transiently Transfected with Different Doses of XBP-
1.eYFP Transcriptional Reporter.  HEK 293 cells were seeded 24 hrs before transfection with the  
XBP-1.pEYFP-N1 reporter construct and treatment with 150 nM TPG.  Sixteen hours after 
treatment cells were collected fixed and analysed by FACS (A). Intact cells were assessed for 
levels of eYFP. The eYFP positive gate was set so that less than 0.1% of the untransfected cells 
fell within the gate. The histogram (B) shows representative results using 0.25 ug reporter 
DNA/105 cells. The graph (C) shows the percent of eYFP positive cells 16hrs after treatment with 
TPG in Hela cells transfected with a range of  reporter plasmid DNA concentrations (ranging 
0.125- 1µg DNA/1x105 cells, UT: Untransfected cells). The changes in the MFI of the eYFP positive 
cells is also shown (D).   
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Figure S2: Optimisation of HEK 293 Cells Transiently Transfected with Different Doses of 
ATF4.eYFP Transcriptional Reporter. HEK 293 cells were seeded 24 hrs before transfection with 
the  XBP-1.pEYFP-N1 reporter construct and treatment with 150 nM TPG.  Sixteen hours after 
treatment cells were collected fixed and analysed by FACS (A). Intact cells were assessed for 
levels of eYFP. The eYFP positive gate was set so that less than 0.1% of the untransfected cells 
fell within the gate. The histogram (B) shows representative results using 0.25 ug reporter 
DNA/105 cells. The graph (C) shows the percent of eYFP positive cells 16hrs after treatment with 
TPG in Hela cells transfected with a range of  reporter plasmid DNA concentrations (ranging 
0.125- 1µg DNA/1x105 cells, UT: Untransfected cells). The changes in the MFI of the eYFP positive 
cells is also shown (D).   
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Figure S3: The Activation of the XBP-1.eYFP Transcriptional Reporter over Time in HEK 293 
Cells after Treatment with TPG. HEK 293s cells were seeded 24 hrs before transfection with 
the  XBP-1.pEYFP-N1 reporter construct and treatment with 150 nM TPG.  Sixteen hours after 
treatment cells were collected fixed and analysed by FACS (A). Intact cells were assessed for 
levels of eYFP. The eYFP positive gate was set so that less than 0.1% of the untransfected cells 
fell within the gate. The histogram (B) shows representative results using 0.25 ug reporter 
DNA/1x105 cells. The graph (C) shows the percent of eYFP positive cells 16hrs after treatment 
with TPG in Hela cells transfected with a range of  reporter plasmid DNA concentrations 
(ranging 0.125- 1µg DNA/1x105 cells, UT: Untransfected cells). The changes in the MFI of the 
eYFP positive cells is also shown (D).   
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